Senaparib/Temozolomide

塞纳帕利/替莫唑胺

Report date: 2025/07/30 14:53:48

Base Information

Drug NameSenaparib/Temozolomide
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitorsDNA inhibitors +[4] 
TargetsPoly (ADP-Ribose) polymerase 1Poly (ADP-Ribose) Polymerase 2DNA
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes SenaparibTemozolomide
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImpact Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Yingpai Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A